Catheter ablation of atrial fibrillation: hope for all highly symptomatic patients.

Česká verzia

Authors: M. Fiala; J. Chovančík; R. Neuwirth; R. Nevřalová; O. Jiravský; I. Nykl; M. Branny
Authors place of work: oddělení kardiologie, Kardiocentrum, Nemocnice Podlesí, a. s., Třinec
Published in the journal: Kardiol Rev Int Med 2006, 8(Supplementum): 28-32

Summary

Atrial fibrillation (AF) is the most prevalent heart rhythm disturbance that is associated with an increased morbidity and mortality. Benefit of maintenance of the sinus rhythm is obvious, however, antiarrhythmic therapy has a limited efficacy. Catheter ablation offers a curative treatment of AF. Ablation strategies reflect the mechanism of arrhythmia initiation and perpetuation. Long-term elimination of paroxysmal AF is currently achieved according to the experience of different centers in 70-90 % of patients. Ablation of chronic AF is less effective, generally not exceeding 60 %. In patients with heart failure and AF, ablation of AF represents, according to the presence of underlying structural heart disease, a potential for improvement or even complete restoration of the systolic left ventricular performance. Ablation for paroxysmal AF resistant to antiarrhythmic drugs in highly symptomatic patients has been becoming a routine reality of the present days. In near future, development of the AF ablation into a method of the first choice or a method, employed in early stages of the disease, can be expected.

Key words:
atrial fibrillation - paroxysmal atrial fibrillation - chronic atrial fibrillation – heart failure – catheter ablation

Zdroje

1. Wolf PA, Benjamin EJ, Belanger AJ et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131: 790-795.

2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.

3. Furberg CD, Psaty BM, Manolio TA et al. CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.

4. Benjamin EJ, Wolf PA, D´Agostino RB et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.

5. Wolf PA, Mitchell JB, Baker CS et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-234.

6. Dries DL, Aarons D, Exner DV et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction. A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703.

7. Pedersen OD, Bagger H, Keller N et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A danish investigators of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104: 292-296.

8. Fromer MA. Indications and limitations of class I antiarrhytmic drugs in atrial fibrillation. Pacing Clin Electrophysiol 1994; 17: 1016-1018.

9. Hohnloser SH. Indications and limitations of class II and III antiarrhytmic drugs in atrial fibrillation. Pacing Clin Electrophysiol 1994; 17: 1019-1025.

10. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.

11. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and ryhthm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.

12. Echt DS, Liebson PR, Mitchel LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788.

13. The Cardiac Arrhythmia Suppression Trial Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233.

14. Waldo AL, Camm AJ deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.

15. Julian DG, Camm AJ, Franglin G et al for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.

16. Cairns JA, Conolly SJ, Roberts R et al. for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent repetitive premature depolarisations: CAMIAT. Lancet 1997; 349: 675-682.

17. Pappone C, Rosanio S, Augello G et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. J Am Coll Cardiol 2003; 42: 185-197.

18. Ho SY, Sanchez-Quintana D, Cabrera JA et al. Anatomy of the left atrium: Implications for radiofrequency ablation of atrial fibrillation. J Cardiovasc Eletrophysiol; 1999; 10: 1525-1533.

19. Moe GK, Rheinboldt WC, Abildskov JA et al. A computer model of atrial fibrillation. Am Heart J 1964; 67: 200-220.

20. Allesie MA, Lammers WJEP, Bonke FIM et al. Experimental evaluation of Moe´s zavelet hypothesis of atrial fibrillation. In: Zipes DP, Kalife J (eds). Cardiac Electrophysiology and Arrhythmias. Orlando: Grune & Stratton 1985.

21. Haïssaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.

22. Mandapati R, Skanes A, Chen J et al. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000; 101: 194-199.

23. Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: A mechanism of atrial fibrillation. Cardiovasc Res 2002; 54: 204-216.

24. Pappone C, Santinelli V, Mantiso F et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109: 327-334.

25. Haïssaguerre M, Jais P, Shah DC et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-1144.

26. Maloney JD, Milner L, Barold S et al. Two-staged biatrial linear and focal ablation to restore sinus rhythm in patients with refractory chronic atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 2527-2532.

27. Haïssaguerre M, Shah DC, Jais P et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 101: 1409-1417.

28. Marrouche NF, Dresing T, Cole C et al. Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation. J Am Coll Cardiol 2002; 40: 464-474.

29. Pappone C, Oreto G, Rosanio S et al. Atrial electroanatomic remodelling after circumferential radiofrequency pulmonary vein ablation. Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104: 2539-2544.

30. Oral H, Scharf C, Chugh A et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108: 2355-2360.

31. Ouyang F, Bänsch D, Ernst S et al. Complete isolation of left atrium surrounding the pulmonary veins. New insights from the double-lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110(15): 2090-2096.

32. Nademanee K, Mckenzie J, Kosar E et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-2053.

33. Marrouche NF, Martin DO, Wazni O et al. Phased-Array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation. Impact on outcome and complications. Circulation 2003; 107: 2710-2716.

34. Chen SA, Hsieh MH, Tai CT et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiologic characteristics, pharmacologic responses, and effects of radiofrequency ablation. Circulation 1999; 100: 1879-1886.

35. Macle L, Jaïs P, Weerasooriya R et al. Irrigated-tip catheter ablation of pulmonary veins for treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2002; 13: 1067-1073.

36. Packer DL, Keelan P, Munger TM et al. Clinical presentation, investigation, and management of pulmonary vein stenosis complicationg ablation for atrial fibrillation. Circulation 2005; 111: 546-554.

37. Pappone C, Oral H, Santinelli V et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004; 109: 2724-2726.

38. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.

39. Hsu LF, Jaïs P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.